Top 20 Series-Rank 19- Concord Biotech- A year of substantial growth

Concord continues to work towards becoming a global power in the field of biotechnology


Organization: Concord Biotech Ltd
CMD: Mr Sudhir Vaid
Bioscience Revenue: Rs 247.95 crore


Ahmedabad-based Concord Biotech, a R&D based biotechnology firm, clocked a total turnover of Rs 253.45 crore in the fiscal 2014-15, out of which the biosciences business contributed Rs 247.95 crore. The company is eyeing Rs 300 crore turnover in the present fiscal.

FY2014-15 has seen Concord launch new products in the market across different therapeutic segments and also collaborated with the formulation players for P-IV products. It is the only manufacturer in India which manufactures the entire range of Immunosuppressant APIs.

The company has launched products in the area of Veterinary, Oncology, Antifungals, Antibiotics and Immunosuppressants. Concord is focused on becoming a strong player in contract research and manufacturing of fermentation and semi-synthesis based products.

This year the company has collaborated with some of the major pharmaceutical players in developing molecules through fermentation and semi-synthesis. In order to cater to the growing demand for its existing and new products, it has added new manufacturing blocks taking the total to 23 manufacturing blocks.
Also in the previous fiscal Concord was re-inspected and approved by the USFDA and the EUGMP.

Concord continues to work towards becoming a global power in the field of biotechnology. In FY2015-16, the company plans to further strengthen its commercial position as well as pipeline product portfolio. It is also focused on contract research and manufacturing of fermentation and semi-synthetic based product and continues to explore opportunities of collaboration globally.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email